Investment Thesis
Nanoviricides is a pre-revenue pharmaceutical company with severe operational challenges, burning cash at an unsustainable rate while generating zero revenue. With only 5.2M in cash, negative operating cash flow of -3.6M annually, and no near-term revenue generation, the company faces critical liquidity risk within 12-18 months absent major financing or operational breakthroughs.
Strengths
- Strong current ratio of 4.43x provides short-term liquidity cushion
- Moderate debt-to-equity ratio of 0.43x shows conservative leverage
- Stockholders equity of 11.1M exceeds total liabilities indicating some balance sheet stability
Risks
- Zero revenue generation with no apparent commercialized products in market
- Negative operating cash flow of -3.6M with only 5.2M cash reserves creates critical runway concern
- Persistent operating losses of -4.0M and ROE of -36.2% indicate fundamental business viability questions
- No insider buying activity in 90 days suggests lack of management confidence
- Long-term debt of 4.7M combined with cash burn creates refinancing risk
Key Metrics to Watch
- Cash burn rate and remaining runway to profitability or capital raise
- Revenue recognition or pipeline advancement in clinical development
- Operating cash flow trajectory and quarterly burn trends
- Debt maturity schedule and refinancing capacity
- Insider trading activity as indicator of management confidence
Financial Metrics
Revenue
0.0
Net Income
-4.0M
EPS (Diluted)
$-0.22
Free Cash Flow
-3.7M
Total Assets
12.3M
Cash
5.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-36.2%
ROA
-32.7%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
4.43x
Quick Ratio
4.43x
Debt/Equity
0.43x
Debt/Assets
9.8%
Interest Coverage
-80.91x
Long-term Debt
4.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-03T16:18:11.156159 |
Data as of: 2025-12-31 |
Powered by Claude AI